LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $7.23B
- P/E (TTM)
- –
- Dividend yield
- –
Legend Biotech Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 57.2%
- Operating margin
- -4.3%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 3.04
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 166.7%
Valuation
- P/E ratio
- –
- Price to sales
- 5.69
- Price to book
- –
- Dividend yield
- –